Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to start review
Explore by Goal
"Science is not only compatible with spirituality; it is a profound source of spirituality."
- Carl Sagan
Quick Explanation
Copied
Dow et al. (2015) established the doxycycline-inducible iCRISPR mouse system, achieving >90% biallelic dual-gene disruption in ESCs and 50-85% in vivo indels in intestine/thymus, with paired-nickase Cas9n reducing off-targets while maintaining phenotype. Quality is high; main limits are leaky Cas9 (33% clones), mosaic p53 loss, and non-genome-wide off-target screening.
Long Explanation
Core Achievement
Dow et al. engineered a col1a1-targeted TRE3G-Cas9 transgene (c3GIC9) with U6-sgRNA cassettes enabling doxycycline-regulated genome editing in adult mice .
Strengths
Frame-shift ratios (~2:1 in ESCs; 97% Apc frameshift in intestine) demonstrate fitness-dependent selection, a clever internal readout of gene function .
Cas9n paired sgRNAs matched Cas9 efficiency in vivo while abolishing the Elk3 off-target β practical specificity gain.
Limitations & Blindspots
33% of ESC clones showed off-doxycycline mutagenesis (leaky Cas9), and 9.6% of F1 offspring carried identical heterozygous mutations, managed only by clonal screening. Off-target assessment surveyed 18 predicted sites with Surveyor β not genome-wide; later unbiased methods (e.g., Digenome-seq) exist . NHEJ-driven indel heterogeneity means 'knockout' is a population mosaic, unlike discrete Cre/lox deletions β authors acknowledge this but mosaicism of p53 staining shows incomplete penetrance. Small n (n=4 tissues, 2 ESC clones) limits power for subtle effects; animal studies were not blinded.
What Would Change the Verdict
Genome-wide off-target sequencing showing frequent unrepaired damage, or failure to reproduce intestinal phenotype in independent iCRISPR strains, would undermine the platform's value; neither is reported here.
Feedback:
Updated: October 08, 2026
BGPT Paper Review
Study Novelty
90%
First demonstration of doxycycline-inducible, transgene-based in vivo CRISPR editing in adult mice (2015), complementing contemporaneous viral approaches.
Scientific Quality
80%
Rigorous multi-level validation (ESCs, organoids, in vivo) with honest acknowledgment of leaky expression and off-targets; weaknesses: small n, Surveyor-based off-target screening, no blinding.
Study Generality
80%
Platform logic (TRE-rtTA + sgRNA cassettes) generalizes across tissues and genes; proof shown in intestine, thymus, liver.
Study Usefulness
90%
Widely adopted template for inducible GEMM modeling; enables conditional knockouts in <6 months without loxP allele engineering.
Study Reproducibility
70%
Detailed methods, but c3GIC9 vectors unavailable via Addgene (TRE3G restriction) and off-dox clone screening adds stochasticity.
Explanatory Depth
70%
Mechanistic insights via frameshift-selection ratios and indel-size analysis; limited molecular depth on off-target and NHEJ determinism.
Simulating indel frequency accumulation over doxycycline exposure days using reported 2-d, 4-d, and 10-d kinetic constraints, with Monte Carlo uncertainty bands for power planning.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
iCRISPR replaces Cre/loxP β authors explicitly reject; NHEJ heterogeneity and mosaicism make it complementary.
Viral CRISPR delivery is superior in vivo β restricted to injectable tissues; transgenic iCRISPR covers any rtTA-expressing tissue.